Claims

1. A lyophilized pharmaceutical formulation comprising an anti-CD38 antibody, a non-ionic surfactant at a concentration of 0.1% (w/w) to 0.2% (w/w) and a histidine buffer of a pH between ~~5.5~~6.0 and 6.5.

2. The lyophilized pharmaceutical formulation of claim 1, wherein said non-ionic surfactant is polysorbate 20.

3. The lyophilized pharmaceutical formulation according to claim 1 or 2, wherein said histidine buffer has a pH of ~~about~~ 6.0.

4. The lyophilized pharmaceutical formulation according to any one of the preceding claims, wherein said anti-CD38 antibody has a HCDR1 of SEQ ID NO.: 1, a HCDR2 of SEQ ID NO.: 2, a HCDR3 of SEQ ID NO.: 3, a LCDR1 of SEQ ID NO.: 4, a LCDR2 of SEQ ID NO.: 5 and a LCDR3 of SEQ ID NO.: 6.

5. The lyophilized pharmaceutical formulation according to any one of the preceding claims, further comprising sucrose.

6. A method for preparing a liquid formulation of an anti-CD38 antibody, said method comprising providing the lyophilized pharmaceutical formulation of any of the preceding claims, and reconstituting said lyophilized formulation via the addition of water.

7. A reconstituted pharmaceutical formulation of an anti-CD38 antibody obtained by the method of claim 6.

8. A reconstituted pharmaceutical formulation according to claim 7, wherein said non-ionic surfactant is at a concentration of ~~0.05% (w/w) to 0.2% (w/w), preferably of about~~ 0.1% (w/w).

9. A reconstituted pharmaceutical formulation according to any one of claims 7 to 8, wherein said histidine buffer is at a concentration of 5 mM to 15 mM~~, preferaby of about 10 mM~~.

10. A reconstituted pharmaceutical formulation according to claim 9, wherein said histidine buffer is at a concentration of 10 mM.

~~10~~11. A reconstituted pharmaceutical formulation according to any one of claims 7 to ~~9~~10, wherein said sucrose is at a concentration of 150 to 350 mM~~, preferably of about 260 mM~~.

12. A reconstituted pharmaceutical formulation according to any one of claim 11, wherein said sucrose is at a concentration of 260 mM.

~~11~~13. A reconstituted pharmaceutical formulation according to any one of claims 7 to ~~10~~12, wherein said anti-CD38 antibody is at a concentration of 55 to 75 mg/ml~~, preferably of about 65 mg/ml~~.

14. A reconstituted pharmaceutical formulation according to claim 13, wherein said anti-CD38 antibody is at a concentration of 65 mg/ml.

~~12~~15. Use of a~~A~~ pharmaceutical formulation of any one of claims 1-5 or 7-~~11~~ 14 ~~for use~~ in the manufacture of a medicament for treatment of a disease or disorder.

~~13~~16. The use of a pharmaceutical formulation according to claim ~~12~~15, wherein said disease or disorder is cancer.

~~14~~17. The use of a pharmaceutical formulation according to claim ~~13~~16, wherein said cancer is a hematological cancer is selected from leukemia, lymphoma and myeloma, such as acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML) and multiple myeloma (MM) or a solid cancer selected from sarcoma and carcinoma, such as breast cancer, ovarian cancer, gastric cancer, lung cancer, pancreatic cancer, prostate cancer, melanoma tumors, colorectal cancer, head and neck cancer, bladder cancer, esophageal cancer, liver cancer, thyroid cancer and kidney cancer.

~~15~~18. The use of a pharmaceutical formulation according to claim ~~12~~15, wherein said disease or disorder is an inflammatory disorder~~.~~,

~~16. The use of a pharmaceutical formulation according to claim 15, wherein said inflammatory disorder is~~ selected from inflammatory bowel disease, rheumatoid arthritis, psoriasis, amyloidosis, systemic lupus erythematosus (SLE), atopic dermatitis, Wegener's granulomatosis, psoriatic arthritis.